Trial Profile
A Randomized, Double Blind, Placebo Controlled, Multicenter Study Evaluating Epoetin Alfa Initiated at 40,000 IU Every Week or 80,000 IU Every Week Versus Placebo in Subjects With IPSS Low- or Intermediate-1 Risk Myelodysplastic Syndromes at Risk For Transfusion
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 May 2014
Price :
$35
*
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Anaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 17 May 2014 New trial record